Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
36
IMMP Quote, Financials, Valuation and Earnings
Last price:
$1.77
Seasonality move
:
2.16%
Day range:
$1.75 - $1.82
52-week range:
$1.32 - $2.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.31x
Volume:
168K
Avg. volume:
133.9K
1-year change:
-15.84%
Market cap:
$247.5M
Revenue:
--
EPS (TTM):
-$0.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $16.49 |
|
MESO
Mesoblast Ltd.
|
$20.3M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMMP
Immutep Ltd.
|
$1.70 | $9.50 | $247.5M | -- | $0.00 | 0% | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.43 | $12.00 | $62.2M | -- | $0.00 | 0% | 3.58x |
|
KZIA
Kazia Therapeutics Ltd.
|
$13.25 | $16.49 | $22.1M | -- | $0.00 | 0% | 598.69x |
|
MESO
Mesoblast Ltd.
|
$16.93 | $35.00 | $2.2B | -- | $0.00 | 0% | 118.82x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 0.345 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Immutep Ltd. vs. Competitors
-
Which has Higher Returns IMMP or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Immutep Ltd.'s net margin of --. Immutep Ltd.'s return on equity of -- beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMMPImmutep Ltd.-- -- -- ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About IMMP or ATHE?
Immutep Ltd. has a consensus price target of $9.50, signalling upside risk potential of 458.82%. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 249.85%. Given that Immutep Ltd. has higher upside potential than Alterity Therapeutics Ltd., analysts believe Immutep Ltd. is more attractive than Alterity Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMMPImmutep Ltd.1 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is IMMP or ATHE More Risky?
Immutep Ltd. has a beta of 1.925, which suggesting that the stock is 92.469% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.023, suggesting its less volatile than the S&P 500 by 97.656%.
-
Which is a Better Dividend Stock IMMP or ATHE?
Immutep Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMMP or ATHE?
Immutep Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Immutep Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Immutep Ltd.'s price-to-earnings ratio is -- while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep Ltd. is -- versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMMPImmutep Ltd.-- -- -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns IMMP or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Immutep Ltd.'s net margin of --. Immutep Ltd.'s return on equity of -- beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital IMMPImmutep Ltd.-- -- -- KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About IMMP or KZIA?
Immutep Ltd. has a consensus price target of $9.50, signalling upside risk potential of 458.82%. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $16.49 which suggests that it could grow by 24.49%. Given that Immutep Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Immutep Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMMPImmutep Ltd.1 0 0 KZIAKazia Therapeutics Ltd.0 0 0 -
Is IMMP or KZIA More Risky?
Immutep Ltd. has a beta of 1.925, which suggesting that the stock is 92.469% more volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock IMMP or KZIA?
Immutep Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMMP or KZIA?
Immutep Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Immutep Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Immutep Ltd.'s price-to-earnings ratio is -- while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep Ltd. is -- versus 598.69x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMMPImmutep Ltd.-- -- -- -- KZIAKazia Therapeutics Ltd.598.69x -- -- --
-
Which has Higher Returns IMMP or MESO?
Mesoblast Ltd. has a net margin of -- compared to Immutep Ltd.'s net margin of --. Immutep Ltd.'s return on equity of -- beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMMPImmutep Ltd.-- -- -- MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About IMMP or MESO?
Immutep Ltd. has a consensus price target of $9.50, signalling upside risk potential of 458.82%. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 106.73%. Given that Immutep Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Immutep Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMMPImmutep Ltd.1 0 0 MESOMesoblast Ltd.1 0 0 -
Is IMMP or MESO More Risky?
Immutep Ltd. has a beta of 1.925, which suggesting that the stock is 92.469% more volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.508%.
-
Which is a Better Dividend Stock IMMP or MESO?
Immutep Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep Ltd. pays -- of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMMP or MESO?
Immutep Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Immutep Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Immutep Ltd.'s price-to-earnings ratio is -- while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep Ltd. is -- versus 118.82x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMMPImmutep Ltd.-- -- -- -- MESOMesoblast Ltd.118.82x -- -- --
-
Which has Higher Returns IMMP or PPCB?
has a net margin of -- compared to Immutep Ltd.'s net margin of --. Immutep Ltd.'s return on equity of -- beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMMPImmutep Ltd.-- -- -- PPCB-- -$0.00 -- -
What do Analysts Say About IMMP or PPCB?
Immutep Ltd. has a consensus price target of $9.50, signalling upside risk potential of 458.82%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Immutep Ltd. has higher upside potential than , analysts believe Immutep Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings IMMPImmutep Ltd.1 0 0 PPCB0 0 0 -
Is IMMP or PPCB More Risky?
Immutep Ltd. has a beta of 1.925, which suggesting that the stock is 92.469% more volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock IMMP or PPCB?
Immutep Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMMP or PPCB?
Immutep Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Immutep Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Immutep Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep Ltd. is -- versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMMPImmutep Ltd.-- -- -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
